-
Johnson & Johnson receives US$465 million opioid ruling reversal
Time of Update: 2021-12-07
As early as 2019, Judge Thad Balkman of Cleveland County, Oklahoma sentenced Johnson & Johnson to deliberately downplay the risks and exaggerate the benefits of opioids, causing the state's opioid addiction crisis.
-
$1.24 billion!
Time of Update: 2021-12-07
On November 9, Pfizer announced that it had reached a cooperation with Biohaven to introduce the company's rights and interests in the company's oral CGRP antagonist Rimegepant (Nurtec®ODT) outside the United States .
-
Global clinical stage III and above small molecule oral new crown drugs inventory new drugs VS old drugs-can catch mice is a good cat!
Time of Update: 2021-12-07
At the same time, procluamide is also the only one in the world Entered into phase III registered clinical trials for small-molecule oral drugs for the treatment of severely ill patients with new coronary disease .
-
my country's new crown specific drugs have a "timetable"
Time of Update: 2021-12-07
According to statistics, there are currently six special drugs for new crowns independently developed in China .
Among them, two effective neutralizing antibody drugs BRII-196 and BRII-198 jointly developed and screened by Tsinghua University, Shenzhen Third People's Hospital and Tengsheng Huachuang have participated in the treatment of more than 700 patients in China .
-
Multinational pharmaceutical companies compete with artificial intelligence in China and are they becoming important players?
Time of Update: 2021-12-07
IDEA Pharma and CNS believe that the use of artificial intelligence technology in the development of the new crown vaccine has put Pfizer on the top, ranking fourth, second and first in terms of commercialization, clinical development, and drug discovery, respectively .
-
The new domestic hypoglycemic medicine is hot! Over 50 types of Class 1 new drugs are coming, Hengrui, Hausen, Haisco... 3 major tracks are racing
Time of Update: 2021-12-06
Including compound preparations, there are currently 9 domestic GLP-1 receptor agonists approved for marketing (2 are domestically produced Class 1 new drugs).
In addition to the two domestically-made GLP-1 receptor agonists that have been approved for marketing, according to incomplete statistics, there are currently 17 domestically-made Class 1 new drugs in phase I and above .
-
The TOP20 market for tens of billions of cold Chinese patent medicines is released! 2 billion large varieties lead, Yunnan Baiyao, Yiling...6 exclusive varieties are on the list
Time of Update: 2021-12-06
As the best-selling category in the retail market, the terminal sales of cold Chinese patent medicines in physical pharmacies in Chinese cities have exceeded 10 billion yuan, and China Resources Sanjiu Pharmaceutical has continued to rank as the top seller .
-
The researchers call on the FDA to strengthen the supervision of clinical trial disclosure, and publish and publish more advance notices of non-compliance
Time of Update: 2021-12-06
Ramachandran and co-authors Christopher Morten and Joseph Ross stated that the 57 advance notices issued by the FDA only “represent one of the thousands of clinical trials applicable to FDAAA that were determined to be non-compliant with the result information reporting requirements as of January 2021.
-
Novartis's $20.7 billion sale of Roche's equity may be used to acquire Alnylam
Time of Update: 2021-12-06
The biotechnology company based in Cambridge, Massachusetts, is the developer of RNA interference (RNAi) technology behind Novartis’s newly acquired cholesterol drug Leqvio (also known as inclisiran), which is expected to soon be approved by the US FDA .
Gene therapy company BioMarin Pharmaceutical is also one of the most attractive potential acquisition targets .
-
Cell therapy technology is changing rapidly, does CAR-T still have advantages?
Time of Update: 2021-12-06
In August of this year, Novartis announced that the CD19 CAR-T therapy Kymriah second-line treatment of aggressive B-cell non-Hodgkin lymphoma (B-NHL) Phase 3 clinical BELINDA did not meet the primary endpoint EFS .
-
2021 Global 100 Medical Device Companies (BIG 100)
Time of Update: 2021-12-06
According to the results of this list, the top ten medical device companies in the top 100 are Medtronic, Johnson & Johnson, Siemens Medical, Philips, Danaher, Myron, GE, Gartner, Essilor Luxentica, and Shisai g , compared to last year, the top 10 in Johnson & Johnson and Medtronic's ranking did not change only continues to dominate the first one and two .
-
CNS: A big market for sleep disorders, new domestic orexin drugs enter Phase 3 clinical trials
Time of Update: 2021-12-06
Chinese Adult Insomnia Diagnosis and Treatment Guidelines (2017 Edition); Chinese Journal of Neurology, 2018,51(5): 324-335; Sleep Disorder Group, Chinese Medical Association Neurology Branch, Chinese Medical Association Neurology Branch; https://mp .
-
Targeted therapy for eosinophilic disease!
Time of Update: 2021-12-06
com) November 17, 2021/Bio Valley BIOON/ - GlaxoSmithKline (GSK) recently announced that the European Commission (EC) has approved the anti-inflammatory drug Nucala (mepolizumab, mepolizumab), which is a kind of A monoclonal antibody that specifically targets interleukin 5 (IL-5) for the treatment of 3 eosinophil-driven diseases: hypereosinophilic syndrome (HES), chronic rhino-sinusitis with nose Polyps (CRSwNP), eosinophilic granulomatous polyangiitis (EGPA) .
-
The results of the co-election of academicians of the two academies in 2021 announced!
Time of Update: 2021-12-06
For the first time, scientists from South Korea and Switzerland were elected foreign academicians of the Chinese Academy of Sciences; 20 foreign academicians were newly elected to the Chinese Academy of Engineering .
-
Entering the high-frequency period, there are five major characteristics of drug purchases with volume!
Time of Update: 2021-12-06
Chongqing’s requirements are to focus on including drugs with large amounts and high purchase amounts in the basic medical insurance drug catalog, and gradually cover all kinds of clinically necessary and reliable drugs on the market in China .
-
Sales in 2021 will remain strong. What is the magic of the HER-2 target of the TOP10 clinical numbers last year?
Time of Update: 2021-12-06
Domestic research and development of HER-2 target remains high In the latest CDE "Annual Report on the Current Status of Clinical Trials for New Drug Registration in China (2020)", the HER-2 target ranked 8th in all dimensions of statistics last year, which is sufficient to illustrate the research and development of HER-2 targets in China The homogeneity is serious .
-
The second HIV "self-healing" person in the world may appear!
Time of Update: 2021-12-06
On November 16, a study published in Annals of Internal Medicine stated that this "Esperanza patient" may be the second HIV-infected person in the world to achieve "self-healing" .
-
Congratulations to the 3 experts of the China Pharmaceutical Innovation Promotion Association for being elected as academicians of the two academies
Time of Update: 2021-12-06
, Representative of the 11th, 12th, and 13th National People's Congress, currently Director of the State Key Laboratory of New Technology of Chinese Medicine Pharmaceutical Process, Director of the National and Local Joint Engineering Research Center for Intelligent Manufacturing of Chinese Patent Medicines, concurrently serving as an executive member of the National Pharmacopoeia Commission, vice president of the Chinese Society of Chinese Medicine, and an executive director of the Chinese Society of Integrative Medicine .
-
IL-36R monoclonal antibody reported for the market, Boehringer Ingelheim's first innovative drug of its kind
Time of Update: 2021-12-06
Boehringer Ingelheim Boehringer Ingelheim is committed to researching breakthrough therapies aimed at improving the health of humans and animals .
Spesolimab IL-36R Boehringer Ingelheim Boehringer Ingelheim has substantially increased its R&D investment since 2020, aiming to develop innovative drugs and therapies for diseases that cannot be effectively treated .
-
Opinions of the General Office of the State Council on Improving the Medical Insurance and Relief System for Major and Serious Diseases
Time of Update: 2021-12-06
The people's governments of all provinces, autonomous regions, and municipalities directly under the Central Government, all ministries and commissions of the State Council, and all directly affiliat
